Vlado Perkovic, professorial fellow at The George Institute, Provost at UNSW Sydney and senior author on the study, said, This research shows that GLP-1 receptor agonists could play an important role in addressing the global burden of non-communicable diseases.
Future research aimed at targeted therapies, improved risk stratification, and individualized treatment approaches may eventually transform CSVD from a progressive and largely irreversible condition into one that can be effectively prevented, monitored, and managed
If you've reached your weight loss goals on a GLP-1 and are wondering whether you'll need to stay on it forever, the answer is: not necessarily
Acknowledgements We thank the 23andMe research participants and employees who made this study possible
Metabolomic analysis of fibrotic mice combined with public RNA-Seq human lung data reveal potential diagnostic biomarker candidates for lung fibrosis
Those with serious chronic illnesses, including diabetes, were excluded